Historical record - last NADAC effective date: 3/21/2018
Product Information
HARVONI 90-400 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $1098.9375 per EA under NDC 61958180101. Its NADAC has been published 217 times since Jan 21, 2015.
FDA first approved this application on Oct 10, 2014.
Strength
90; 400 mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958180101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
3/21/2018
Active Ingredients
LEDIPASVIR; SOFOSBUVIRApproval Type
New Drug (NDA)
FDA Application
NDA205834FDA Approved
10/10/2014
On Market Since
10/10/2014
Pharmacological Classes
Price Statistics
The NADAC for HARVONI 90-400 MG TABLET has been published 217 times since Jan 21, 2015, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1098.9375 per EA |
|---|---|
| All-time high | $1101.1809 (Oct 11, 2017) |
| All-time low | $1084.6350 (Oct 18, 2017) |
| Median price | $1096.1906 |
| Average price | $1094.3722 |
| Largest weekly change | -1.5% (Oct 18, 2017) |
| Weeks tracked | 217 |
| Tracking since | Jan 21, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+0.7%
Last surveyed Mar 13, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LEDIPASVIR and SOFOSBUVIR market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LEDIPASVIR and SOFOSBUVIR market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis C Virus NS5A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HARVONI 90-400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HARVONI 90-400 MG TABLET, manufactured by Gilead Sciences, Inc., is $1098.9375 per EA (NDC 61958180101), effective Mar 13, 2019.
How has the price of HARVONI 90-400 MG TABLET changed over time?
Over the history we have for it, the NADAC for HARVONI 90-400 MG TABLET has held within roughly two percent of its current level. It has been tracked across 217 weekly CMS publications since Jan 21, 2015.
What are the highest and lowest recorded NADAC prices for HARVONI 90-400 MG TABLET?
Since Jan 21, 2015, the NADAC for HARVONI 90-400 MG TABLET has ranged from a low of $1084.6350 (Oct 18, 2017) to a high of $1101.1809 (Oct 11, 2017), with a median of $1096.1906 per EA.
Are there cheaper alternatives to HARVONI 90-400 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of HARVONI 90-400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures HARVONI 90-400 MG TABLET?
HARVONI 90-400 MG TABLET (NDC 61958180101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.